Therapeutic contribution of PCSK9 inhibitors

被引：0
作者：
Millan Nunez-Cortes, Jesus [1 ]
Pedro-Botet, Juan [2 ]
机构：
[1] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Unidad Riesgo Vasc & Lipidos, Madrid, Spain
[2] Univ Autonoma Barcelona, Hosp del Mar, Unitat Lipids & Risc Vasc, Barcelona, Spain
来源：
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS | 2016年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：39 / 41
页数：3
相关论文
共 6 条
  • [1] Monoclonal antibodies against PCSK9: from bench to clinic
    Guijarro Herraiz, Carlos
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 14 - 21
  • [2] Lopez Miranda J, 2016, CLIN INVEST ARTER S2, V28, P31
  • [3] Unmet needs: patients with statin intolerance or familial hypercholesterolemia
    Masana, Luis
    Civeira, Fernando
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 22 - 30
  • [4] Lipid-lowering drugs and PCSK9
    Millan Nunez-Cortes, Jesus
    Mostaza Prieto, Jose M.
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 9 - 13
  • [5] Pedro-Botet J, 2016, CLIN INVEST ARTERIOS, V28, P1, DOI 10.1016/S0214-9168(16)30163-2
  • [6] PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects
    Pedro-Botet, Juan
    Badimon, Lina
    [J]. CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 3 - 8
1